Coronary Artery Disease - Eighth International Congress. From prevention to intervention.
The International Congress on Coronary Artery Disease, held in Prague, included topics covering new developments in the field of therapeutics for cardiovascular diseases. This conference report highlights selected presentations on clinical and basic research, including the future of interventional cardiology, treatments to accompany percutaneous coronary intervention, vascular closure devices, the use of heparin and clopidogrel, applying differential matrix metalloprotease profiling and microRNAs to identify patients for treatment, targeting cathepsins in atherosclerosis, and targeting cholesterol in cardiovascular disease. Investigational drugs discussed include FX-06 (Ikaria Holdings Inc) and RVX-208 (Resverlogix Corp).
Wong
Norman C W
NC
University of Calgary, Health Science Centre, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada. ncwwong@ucalgary.ca
D015906:Angioplasty, Balloon, Coronary / Q000379:methods; D000818:Animals; D002317:Cardiovascular Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy*; D003324:Coronary Artery Disease / Q000503:physiopathology / Q000517:prevention & control / Q000628:therapy; D015195:Drug Design; D015507:Drugs, Investigational / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans
D002317:Cardiovascular Agents; D015507:Drugs, Investigational